Navigation Links
Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/4/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2012 at 2:00 p.m. PT / 5:00 p.m. ET. Greg I. Frost, Ph.D., president and chief executive officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The Company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's ENHANZE™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition to partnerships that use Halozyme's ENHANZE™ Technology, the Company has a number of product candidates in its pipeline that target multiple areas of significant unmet medical need. For more information, visit www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com

 


'/>"/>
SOURCE Halozyme
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
2. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
3. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
4. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
5. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
6. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
7. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
8. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
9. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
10. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
11. Halozyme Receives $5.5 Million Payment From Baxter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of ... to their offering. ... , , An ... is anticipated. Nanotechnology will be applied at all stages of ... applications in clinical trials. Many of the assays based on ...
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced that the ... will take place on February 1-3, 2017 at the Roosevelt Hotel in New York ... program provides a unique 360-degree approach, which addresses the most up-to-date information regarding business ...
(Date:12/2/2016)... 2016   SurePure, Inc. (OTCQB: SURP) a ... Company has concluded an agreement with Tamarack Biotics under ... period to acquire units of the Company,s patented photopurification ... million.  Concurrently with the option, SurePure ... Tamarack will seek regulatory approvals in the ...
(Date:11/30/2016)... November 30, 2016 The global ... players hold a dominant share in the overall market. ... International, Inc., and Merck KGaA, held a lion,s share ... Market Research observes that these companies are expected to ... products that are do not require rabbit pyrogen testing ...
Breaking Biology Technology:
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/16/2016)... Calif. , Nov. 16, 2016 ... user experience and security for consumer electronics, and ... the financial and retail industry, today announced a ... and convenient way to authenticate users of mobile ... Sensory,s TrulySecure™ software which requires no ...
Breaking Biology News(10 mins):